The clinical validity and utility of combinatorial pharmacogenomics: Enhancing patient outcomes

Applied and Translational Genomics

Volumn 5, Issue , 2015, Pages 47-49

  Benitez, Joachim ^a   Jablonski, Michael R ^b   Allen, Josiah D ^b   Winner, Joel G ^b,c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Assurex Health   (United States)

^c Winner Psychiatry   (United States)

Author keywords

Combinatorial pharmacogenomics; Major depressive disorder; Neurogenetics; Psychiatry

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450 2D6; PSYCHOTROPIC AGENT;

ARTICLE; CLINICAL TRIAL (TOPIC); CLINICIAN RATED QUICK INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY; COST CONTROL; DEPRESSION; DEPRESSION ASSESSMENT; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; GENE LOCUS; GENETIC ANALYSIS; GENETIC VARIABILITY; HAMILTON DEPRESSION RATING SCALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MEDICAL DECISION MAKING; MENTAL HEALTH CARE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT HEALTH QUESTIONNAIRE; PHARMACOGENOMICS; PRESCRIPTION; PRIORITY JOURNAL; VALIDITY;

EID: 84952630129     PISSN: 22120661     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atg.2015.03.001     Document Type: Article

References (20)

1. Allen J.D., Carhart J.M., Spivak A.J., Dechairo B.M. GeneSight Psychotropic Reduces Overall Medication Cost in Patients Treated with Psychiatric Medications Poster presentation at the American Psychiatric Association Annual Meeting 2014, (New York, NY).
2. Allen J.D., Carhart J.M., Winner J.G., Marshak A.G., Dechairo B.M. GeneSight Psychotropic Decreases Medication Costs in a Large, Prospective Case-control Project Poster presentation at the Neuroscience Education Institute (NEI) Psychopharmacology Congress 2014, Colorado Springs, CO.
3. Altar C.A., Carhart J.M., Allen J.D., Hall-flavin D.K., Dechairo B.M., Winner J.G. Clinical Validity: Combinatorial Pharmacogenomics Predicts Antidepressant Responses and Healthcare Utilizations Better Than Single Gene Phenotypes 2015, 1-9. 10.1038/tpj.2014.85.
4. Center for Medicare and Medicaid Services, Coverage Database Medicare Local Coverage Determination (LCD): MoPath:GENESIGHT® Assay for Refractory Depression (L35437), 2014. retrieved from http://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=35437&ContrId=228&ver=3&ContrVer=2&SearchType=Advanced&CoverageSelection=Local&ArticleType=SAD%7cEd&PolicyType=Final&s=All&KeyWord=GeneSight&KeyWordLookUp=Title&KeyWordSearchType=Exact&kq=true&bc=IAAAABAAAAAAAA%3d%3d 2014, October 24.
5. Chou W.H., Yan F.X., de Leon J., Barnhill J., Rogers T., Cronin M., Pho M., Xiao V., Ryder T.B., Liu W.W., Teiling C., Wedlund P.J. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J. Clin. Psychopharmacol. 2000, 20:246-251.
6. Dalén P., Dahl M.L., Bernal Ruiz M.L., Nordin J., Bertilsson L. 10-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin. Pharmacol. Ther. 1998, 63:444-452. 10.1016/S0009-9236(98)90040-6.
7. Evaluation of Genomic Applications in Practice Recommendations from the EGAPP working group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet. Med 2007, 9:819-825. 10.1097/GIM.0b013e31815bf9a3.
8. Fagerness J., Fonseca E., Hess G.P., Scott R., Gardner K.R., Koffler M., Fava M., Perlis R.H., Brennan F.X., Lombard J. Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings. Am. J. Manage Care 2014, 20:146-156.
9. Hall-Flavin D.K., Winner J.G., Allen J.D., Jordan J.J., Nesheim R.S., Snyder K.a, Drews M.S., Eisterhold L.L., Biernacka J.M., Mrazek D.a Using a pharmacogenomic algorithm to guide the treatment of depression. Transl. Psychiatry 2012, 2:e172. 10.1038/tp.2012.99.
10. Hall-Flavin D.K., Winner J.G., Allen J.D., Carhart J.M., Proctor B., Snyder K.a, Drews M.S., Eisterhold L.L., Geske J., Mrazek D.a Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet. Genomics 2013, 23:535-548.
11. Hamilton S.P. The Promise of psychiatric pharmacogenomics. Biol. Psychiatry 2015, 77:29-35. 10.1016/j.biopsych.2014.09.009.
12. Howland R.H. Pharmacogenetic testing in psychiatry: Not (quite) ready for primetime. J. Psychosoc. Nurs. Ment. Health Serv. 2014, 52:13-16. 10.3928/02793695-20141021-09.
13. Mrazek D.A., Rush A.J., Biernacka J.M., O'Kane D.J., Cunningham J.M., Wieben E.D., Schaid D.J., Drews M.S., Courson V.L., Snyder K.A., Black J.L., Weinshilboum R.M. SLC6A4 variation and citalopram response. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2009, 150B:341-351. 10.1002/ajmg.b.30816.
14. Olesen O.V., Linnet K. Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes. Pharmacology 1999, 59:298-309.
15. Porcelli S., Fabbri C., Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur. Neuropsychopharmacol. 2012, 22:239-258. 10.1016/j.euroneuro.2011.10.003.
16. Ruaño G., Szarek B.L., Villagra D., Gorowski K., Kocherla M., Seip R.L., Goethe J.W., Schwartz H.I. Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive disorder. Biomark. Med 2013, 7:429-439. 10.2217/bmm.13.16.
17. Rundell J.R., Staab J.P., Shinozaki G., Saad-Pendergrass D., Moore K., McAlpine D., Mrazek D. Pharmacogenomic Testing in a tertiary care outpatient psychosomatic medicine practice. Psychosomatics 2011, 52:141-146. 10.1016/j.psym.2010.12.023.
18. Warden D., Rush a J., Trivedi M.H., Fava M., Wisniewski S.R. The STAR*D project results: a comprehensive review of findings. Curr. Psychiatry Rep. 2007, 9:449-459.
19. Winner J., Allen J.D., Anthony Altar C., Spahic-Mihajlovic a Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Transl. Psychiatry 2013, 3:e242. 10.1038/tp.2013.2.
20. Winner J.G., Carhart J.M., Altar C.A., Allen J.D., Dechairo B.M. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discov. Med. 2013, 16:219-227.